TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
WEAK BUY

Pfizer Inc(PFE)

Dec 22, 2010
Coming out of the recession pharmaceuticals have not recovered to 2007 levels. Market worries about Obamacare and generics impact on branded drugs. Also worried about FDA approval process.. Also subject to litigation. Tremendous amount of cash and trading at very low multiples. Looking at this.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$17.56

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 17, 2010
Have had a lot of issues and the CEO has left. Has been an abysmal investment over the last 5-10 years. Decent dividend. What do they do when Lipitor goes off patent mid 2011? Their acquisition of Wyeth gives them a decent stream of products. Trading at 8X earnings. Everybody hates it so maybe it’s worth looking at.
Photo of Gavin GrahamGavin GrahamUnlock Rating
$17.03

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 16, 2010
Looked at it a couple of times. Lots of cash, good name, but he has never been able to pull the trigger. He thinks you need to let it go up a bit and increase volume, but if you own it, you get paid to wait.
Photo of Rick StuchberryRick StuchberryUnlock Rating
$17.22

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 19, 2010
Concerned with risk from generic competition to the big pharmas. Prefers Teva (TEVA-Q). The big pharmas will continue to struggle because of this.
Photo of Karl BergerKarl Berger
No
Unlock Rating
$16.80

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 10, 2010
Lost its ability to grow because of its size. Lipitor represents 20% and it goes off patent next year so they’ll be competing with generics.
Photo of Gordon ReidGordon ReidUnlock Rating
$16.83

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 09, 2010
(Top Pick Nov 16/09, Down 5%) Drug stocks have been out of favour. Drug stocks bottomed earlier this year. Have a number of drugs coming off patent. Dividend investors have identified drug companies as targets.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$16.83

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 08, 2010
(Top Pick Nov 30/09, Down 4.77%) $28.23 model price. 64% upside. He keeps on buying it. Held for 4 years in his fund. There is value there and major consolidation going on there. It’s a changing landscape – they are getting together with generics.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.05

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Oct 20, 2010
The whole pharma business is somewhat challenged. They spend lots developing a drug and then a few years later it goes Generic. One drug is a quarter of their business but it goes Generic in 2011. There are better places to go. This is more of a defensive stock. Would prefer a hybrid that just has pharma as a part of the their business.
Photo of Gordon ReidGordon ReidUnlock Rating
$17.66

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 05, 2010
(A Top Pick Oct 8/09. Up 5.36%.) Still likes.
Photo of Colin StewartColin Stewart
Owned
Unlock Rating
$17.23

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Sep 07, 2010
Has been a long-term sufferer. Product outlook is much better since the merger. They have started to increase their dividend again. This is a dividend stock with some upside potential.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$16.33

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

May 25, 2010
(Market Call Minute) Doesn’t buy US stocks.
Photo of Barry SchwartzBarry SchwartzUnlock Rating
$15.06

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 21, 2010
Pharma model, i.e. spending a boatload of money developing drugs and getting it into market, is really stumbling. Then the clock starts ticking with generics coming in down the road. Lipitor expires next year.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$16.60

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 14, 2010
Their big drug Lipitor comes off patent next year, which will be a lot of revenue that will be difficult to replace. Have an “OK” pipeline. Because of their size, it takes a huge blockbuster drug to turn the needle to a positive direction.
Photo of Don LatoDon LatoUnlock Rating
$17.07

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Apr 12, 2010
$2 in annualized earnings. Very cheap stock. Doesn't have the growth that it used to. Have global growth and is a beneficiary of the decline in the US$.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$17.29

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Apr 08, 2010
Like it for its dividend of about 4.1%. Very high cash flow. Have diversified their product line with the acquisition of Wyeth.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$17.14

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 451 to 465 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like